Keyword: BioMarin Pharmaceutical

BioMarin is collaborating again with Believe Limited for an arts program to support people with hemophilia.

BioMarin and Invitae are expanding their free genetic testing program for children with seizures with new partners and a wider patient age range.

BioMarin and NICE have been negotiating for a year, but that hasn’t helped the company secure reimbursement for its Batten disease drug.

M&A will help the biopharma industry deal with significant new challenges, Morningstar said, including pressure from lawmakers and payers to lower prices.

The BioMarin-sponsored musical created by teens with hemophilia debuts today after a weekend of practice, camaraderie and education.

BioMarin is already expanding its manufacturing site in Ireland, adding more than 50 jobs in the process.

BioMarin and Believe Limited are helping 25 high schoolers create the first-ever musical about bleeding disorders.

With a dreaded black box warning on the label, and an estimated average cost of $192,000, Biomarin will face challenges marketing its new PKU drug Palynziq.

This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?

BioMarin knows winning drug names. For the second time, one of its drugs won our #FierceMadness tournament—thanks in large part to BioMarin employees.